hrHPV阴性vs细胞学阴性筛查后宫颈癌长期风险:人群研究
基于荷兰全国病理数据库,比较2014年细胞学筛查与2017年hrHPV筛查中未转诊女性的长期宫颈癌风险。hrHPV阴性女性间期癌风险较细胞学正常者低50%,纳入下一轮癌症后低60%。hrHPV阳性但细胞学阴性未转诊者风险最高,为细胞学阳性未转诊者的3.4倍。
要点
- hrHPV阴性者间期癌风险较细胞学正常者低50%(HR 0.5)。
- hrHPV阳性但细胞学阴性未转诊者癌风险最高,为细胞学阳性者的3.4倍。
- 结果支持延长hrHPV阴性女性的筛查间隔,并提示需优化hrHPV阳性分流指南。
核心结论
- hrHPV阴性筛查后长期宫颈癌风险低于细胞学正常,支持延长hrHPV阴性女性筛查间隔。
- hrHPV阳性但细胞学阴性未转诊者风险显著升高,提示可能需要替代分流指南。
研究设计与样本
- 基于荷兰全国病理数据库(Palga)的人群研究。
- 纳入2014年细胞学筛查未转诊女性469,116例和2017年hrHPV筛查未转诊女性362,128例,共4,071,690人年。
- 分析未转诊后宫颈癌风险,包括间期癌和下一轮筛查检出的癌症。
主要发现
- 细胞学筛查未转诊者间期癌发病率为3.3/10万人年,hrHPV筛查未转诊者为2.7/10万人年。
- 纳入下一轮癌症后,上述发病率分别升至5.7和4.5/10万人年。
- hrHPV阴性女性间期癌风险较细胞学正常者低50%(HR 0.5;95%CI 0.3-0.8),纳入下一轮癌症后低60%(HR 0.4;95%CI 0.3-0.5)。
- hrHPV阳性未转诊女性间期癌24/10万人年,纳入下一轮癌症后升至45/10万人年。
- hrHPV阳性未转诊者风险为细胞学阳性未转诊者的3.4倍(间期癌HR 3.4;95%CI 1.1-8.1;纳入下一轮癌症HR 3.4;95%CI 1.4-8.1)。
临床怎么用
- hrHPV阴性女性可考虑延长筛查间隔。
- hrHPV阳性但细胞学阴性的未转诊女性需关注较高癌症风险,可能需要优化分流策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized trials have shown that hrHPV-testing provides better protection against cervical cancer than cytology. However, long-term assessment of programme sensitivity remains essential. In the Netherlands, hrHPV-screening replaced cytology in 2017. We estimated the long-term cervical cancer risk following negative results in hrHPV- versus cytology-based screening. METHODS: Screening and histology data from the nationwide Dutch pathology databank (Palga) were used to identify 469,116 women without referral in 2014 (cytology-based) and 362,128 in 2017 (hrHPV-based), representing 4,071,690 person-years. Cervical cancer risk following non-referral, including interval cancers (IC) and those detected in the next screening round were analysed. FINDINGS: The incidence rate per 100,000 person-years was 3.3 IC following non-referral in cytology-based versus 2.7 following non-referral in hrHPV-based screening. Including next-round cancers, these numbers increase to 5.7 and 4.5. HrHPV-test negative women had a 50 % lower IC risk compared to those with normal cytology (HR 0.5; 95 % CI: 0.3-0.8), and 60 % lower when including next-round cancers (HR 0.4; 95 % CI: 0.3-0.5). HrHPV-positive women without referral had the highest cancer risk: 24 IC per 100,000 person-years, rising to 45 when including next-round cancers. Their risk was 3.4 times higher than for women with positive primary cytology without referral (HR: 3.4; 95 % CI: 1.1-8.1 for IC and HR: 3.4; 95 % CI: 1.4-8.1 including next-round cancers). INTERPRETATION: A negative hrHPV test was linked to lower long-term risk of cervical cancer than normal cytology, supporting longer screening intervals for hrHPV-negative women. However, hrHPV-positivity with negative cytology was associated with increased risk, suggesting the possible need for alternative triage guidelines.
引用
- Schevenhoven VJC, Jansen EEL, Siebers AG, et al. Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study. Eur J Cancer. 2026. PMID: 41759414. doi:10.1016/j.ejca.2026.116601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。